46-53 of 53
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
CME/CEPatient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
Finally, I Can Take a Break from My Itch! Optimizing CKD-aP Treatment
CME/CEFinally, I Can Take a Break from My Itch! Optimizing CKD-aP Treatment
Getting to the Root of CKD-Associated Pruritus: Questions From the Field
CME/CEGetting to the Root of CKD-Associated Pruritus: Questions From the Field
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
CME/CEApplying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Why We Should Be PRO Patients With CKD-Associated Pruritus
CME/CEWhy We Should Be PRO Patients With CKD-Associated Pruritus
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
CME/CEDirected Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
- advertisement
KALMing the Itch: Improving QoL in Patients with CKD-aP
CME/CEKALMing the Itch: Improving QoL in Patients with CKD-aP
Separating Fact from Fiction: The Realities of CKD-aP
CME/CESeparating Fact from Fiction: The Realities of CKD-aP
